Scrip Asks…What Does 2023 Hold For Biopharma? Part 7: Clinical Trial Trends

Decentralize, Diversify And Prioritize The Patient

From synthetic data to real-world data, from patient engagement to patient stratification, from combination trials to master protocols and from fully decentralized through hybrid to onsite trials, the world of clinical development is undergoing major changes. Fifty executives share their predictions around clinical trial trends for the year ahead.

Clinical Trial Trends
• Source: Shutterstock

Some three years after COVID-19 kickstarted a massive adoption of digital technology and shift to remote monitoring in clinical development, technology continues to effect seismic changes in the trials landscape. Clinical trials have always been about data but our ability to capture more data in more ways and to generate more meaningful clinical insights from a wider range of data sources has exploded. Industry has the potential to fine-tune trials, identifying and enrolling only those patients most likely to benefit, pursuing endpoints that are meaningful to patients and saving time and money.

More from Scrip Asks

Scrip Asks… What Does 2025 Hold For Biopharma? Part 1: The State Of The Biopharma Industry

 

More than 40 industry executives shared their views on where the biopharma industry stands as it enters the new year. Innovation remains the sector’s driving force, but after two years of capital constraint, due diligence is key.

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

 

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends

 

Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.

Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology

 

More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.

More from Scrip

GSK-Backed Ouro Launches With $120m For T-Cell Engagers In Autoimmune Diseases

 
• By 

Ouro Medicines, founded by Monograph Capital and GSK and helmed by HI-Bio veterans, aims to reset the immune system in B-cell-mediated diseases with options that are not CAR-T therapies.

Finance Watch: Aviceda, Tenvie Among Flurry Of Pre-J.P. Morgan VC Financings

 
• By 

Private Company Edition: Biopharma firms revealed new VC funding to highlight progress ahead of the J.P. Morgan Healthcare Conference, including Aviceda’s $207.5m series C round, Tenvie’s $200m launch, a $115m series B for Aspect Biosystems and a €90m ($93.4m) series A for Orbis.

Venture Fund Aims To Enrich Chugai’s Discovery Engine

 

The head of Chugai's new $200m venture capital fund talks to Scrip about its investment priorities.